Ministry of Health (Israel)

Israeli Ministry of Health Reports Surge in Medical Cannabis Patients Following Recent Events

Retrieved on: 
Tuesday, November 7, 2023
Cannabis, FDA, Spectrum, Intelligence, Psychiatry, Ageing, Ministry of Health (Israel), Family, Physician, Data collection, BYND, Pain Clinic, CSE, Ministry, BCAN, CRM, Epilepsy, Patient, Software as a service, Nursing, Pharmaceutical industry

Recent regulatory reforms approved by the Israeli Ministry of Healthi allows physicians to prescribe cannabis to patients as a first-line treatment rather than as an option of last resort.

Key Points: 
  • Recent regulatory reforms approved by the Israeli Ministry of Healthi allows physicians to prescribe cannabis to patients as a first-line treatment rather than as an option of last resort.
  • Israel has had a significant increase in the number of licensed medical cannabis patientsii in the wake of recent events, particularly the opening of the war in Gaza.
  • Physicians licensed to prescribe medical cannabis and Israeli Ministry of Health authorities have reported a notable surge in demand after the recent conflict.
  • Many of the medical cannabis patients receiving new licenses are war casualties, as doctors began issuing licenses for post-trauma to victims of the recent events.

IMC welcomes new Israeli cannabis regulations which are about to change significantly, facilitating access for many new patients

Retrieved on: 
Friday, August 11, 2023
Epilepsy, CSE, Ministry of Health (Israel), Colitis, Multiple sclerosis, Crohn's disease, Certification, Ministry, Ministry of Health, Dementia, AIDS, Management of Tourette syndrome, Patient, Palliative care, Spectrum, Cannabis, Growth, IMCC, Medicinal plants, Drug, IMC, EU, Health, Parkinson's disease

TORONTO and GLIL YAM, Israel, Aug. 11, 2023 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company" or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to share the new medical cannabis reform announced by the Israeli ministry of health on August 7, 2023 (the "Reform").

Key Points: 
  • The Israeli ministry of health announced the anticipated medical cannabis regulatory reform on Monday August 7, 2023.
  • The new regulations will remove many of the heavy regulations in the sector, making medical cannabis more accessible to patients as well as boosting export.
  • All Israeli patients suffering from these indications will be able to have access to medical cannabis with a regular prescription.
  • "With the overhaul of the cannabis regulation, the Israeli Ministry of Health is clearly putting patient needs first, facilitating the access of medical cannabis for many new patients.

IMC welcomes new Israeli cannabis regulations which are about to change significantly, facilitating access for many new patients

Retrieved on: 
Friday, August 11, 2023
Epilepsy, CSE, Ministry of Health (Israel), Colitis, Multiple sclerosis, Crohn's disease, Certification, Ministry, Ministry of Health, Dementia, AIDS, Management of Tourette syndrome, Patient, Palliative care, Spectrum, Cannabis, Growth, IMCC, Medicinal plants, Drug, IMC, EU, Health, Parkinson's disease

TORONTO and GLIL YAM, Israel, Aug. 11, 2023 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company" or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to share the new medical cannabis reform announced by the Israeli ministry of health on August 7, 2023 (the "Reform").

Key Points: 
  • The Israeli ministry of health announced the anticipated medical cannabis regulatory reform on Monday August 7, 2023.
  • The new regulations will remove many of the heavy regulations in the sector, making medical cannabis more accessible to patients as well as boosting export.
  • All Israeli patients suffering from these indications will be able to have access to medical cannabis with a regular prescription.
  • "With the overhaul of the cannabis regulation, the Israeli Ministry of Health is clearly putting patient needs first, facilitating the access of medical cannabis for many new patients.

SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder

Retrieved on: 
Friday, July 14, 2023
Communication, Ministry of Health (Israel), Status epilepticus, Central nervous system, Social, Spectrum, Professional, Clinical trial, Tourette syndrome, Clinical Global Impression, IMCA, Agitation, Sale, Pain, Ministry, TEL, Behavior, ASD, Deviance (sociology), Cannabis, THC, Alzheimer's disease, Cannabidiol, Safety, Pharmaceutical industry, Vaccine, Health, CBD

TEL AVIV, Israel, July 14, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has been granted an approval from the Israeli Medical Cannabis Agency ("IMCA") at the Israeli Ministry of Health to conduct its clinical trial for SCI-210 in children suffering from autism spectrum disorder ("ASD"). SCI-210 is a proprietary combination of cannabidiol (“CBD”) and CannAmide™.

Key Points: 
  • "The initiation of this clinical trial represents a significant step forward for our proprietary SCI-210 as we work to develop a novel treatment for children and adolescents with ASD.
  • The design of the study includes a 20-week, randomized double-blind placebo-controlled with cross-over clinical trial of 60 children.
  • The trial was designed in consultation with the National Autism Research Center, the leading research center for autism in Israel.
  • The term "spectrum" in autism spectrum disorder refers to the wide range of symptoms and severity.

Ohh-Med Announces 1500th Satisfied Customer for Vertica®, the Breakthrough Home-Use Device to Treat Erectile Dysfunction

Retrieved on: 
Wednesday, May 31, 2023
Heart, Friends, Trial of the century, Ministry of Health (Israel), Ministry, Erectile dysfunction, ED, VC, Family, Pharmaceutical industry, EU, Vertica

TIBERIAS, Israel , May 31, 2023 /PRNewswire/ -- Ohh-Med, a medtech startup located in the Tiberias Industrial Zone, has developed Vertica, a medical device designed to improve the lives of thousands of men who experience erectile dysfunction (ED). Vertica received Israel Ministry of Health approval to sell directly to consumers in June 2021, and in December 2022, Vertica received the CE-MDR approval to market throughout the EU. The company markets its product in Israel direct to consumers through its online shop, and in Europe through a growing network of distributors.  Ohh-Med was established with seed money and an initial investment by a local VC.

Key Points: 
  • The company markets its product in Israel direct to consumers through its online shop, and in Europe through a growing network of distributors.
  • Ohh-Med was established with seed money and an initial investment by a local VC.
  • "We are thrilled to celebrate our 1500th satisfied user of Vertica.
  • The company places the consumer at the heart of the company and has established its own Customer Support Hotline to address each caller individually and with sensitivity.

Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update

Retrieved on: 
Monday, March 27, 2023
Research, Clinical Trials, Health Technology, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, Haematopoiesis, Ministry of Health (Israel), EAP, University, ASH, Therapy, Integrin alpha-1, CD16, T&E, CD57, Neoplasm, Survival, NK, Toxicity, Tandem, Cell, IP, Rated R, LAMP1, TCT, Ministry, Incidence, Highbridge Capital Management, Center for International Blood and Marrow Transplant Research, LAG3, Patient, CD56, University of Minnesota Medical School, CD62L, PDUFA, Viral, Poster, FDA, Society, Safety, Cryptocurrency, Pharmaceutical industry, Dentistry, Vaccine, Security (finance), Transplant

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the year ended December 31, 2022.

Key Points: 
  • Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for the year ended December 31, 2022.
  • As of December 31, 2022, Gamida Cell had total cash and cash equivalents of $64.7 million.
  • “Our mission is to bring potentially curative therapies to patients,” said Abbey Jenkins, President and Chief Executive Officer of Gamida Cell.
  • Especially since our engineered NK cell therapy candidates, which are derived from healthy donors, have demonstrated encouraging pre-clinical data that differentiate them from other NK cell therapy approaches.

SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome

Retrieved on: 
Thursday, March 9, 2023
Yale Global Tic Severity Scale, TEL, Psychiatry, Tel Aviv Sourasky Medical Center, Clinical trial, Yale School of Medicine, Yale University, Estonia, Patient, Tourette syndrome, Yale Child Study Center, Hannover Medical School, Central nervous system, TS, Ministry, Department of Neurology, Xuanwu hospital, Ministry of Health (Israel), Medical device, Safety, Pharmaceutical industry, Neurology

TEL AVIV, Israel, March 09, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the approval of the Israeli Ministry of Health to conduct its clinical trial titled “A randomized, double-blind, placebo controlled, cross-over study to evaluate the efficacy, safety and tolerability of daily oral SCI-110 in treating adults with Tourette Syndrome”.

Key Points: 
  • The first clinical site to receive approval to conduct the trial is Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, under the leadership of Prof. Tanya Gurevich, Head of Movement Disorders Unit, Department of Neurology.
  • “We are excited to be granted approval to conduct our Tourette Syndrome (“TS”) clinical trial in Israel.
  • This is another step for the Company's progress in the developments of much needed treatment for TS.
  • "TS is estimated to affect 0.5-1% of the world's population, however the very few available treatments have limited efficacy and questionable safety.

SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome

Retrieved on: 
Monday, March 6, 2023
Yale University, Hannover Medical School, Tel Aviv Sourasky Medical Center, Movement, European Medicines Agency, Ministry of Health (Israel), Ministry, Tic, TEL, TS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Central nervous system, Patient, Learning, Tourette syndrome, Food, Yale Global Tic Severity Scale, Institutional review board, Ethics, FDA, Ministry of Health, Medical device, Safety, Pharmaceutical industry, Health

The Company has already received ethics committee approvals from the Hannover Medical School in Hannover, Germany, and the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel.

Key Points: 
  • The Company has already received ethics committee approvals from the Hannover Medical School in Hannover, Germany, and the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel.
  • The Company is currently preparing to submit a request for approval to the Institutional Review Board of Yale University, Connecticut, USA (“Yale’s IRB”).
  • Tics may be associated with a premonitory sensation to perform a specific action, which may lead to “relief” once performed.
  • “With the successful manufacturing of the clinical batches, we are one step closer to initiate this important clinical trial.”

Decentralized Trials & Research Alliance (DTRA) Shares Key Findings from Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
SAN, GLOBE, Priority, Data collection, DTRA, DCTS, Mission, CVS, Annual, Method, DCT, Data technology, Danish Medicines Agency, Annual general meeting, Ministry, Proceedings of the Human Factors and Ergonomics Society Annual Meeting, Research, Education, Adoption, Ministry of Health (Israel), BMS, Evidence, Alaska Federal Health Care Access Network, Cros, EMA, Publication, Entrepreneurship, Decentralized Trials & Research Alliance, Sanofi, Industry, FDA, Pharmaceutical industry, Renewable energy, Risk management, Parexel

SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA), a non-profit organization dedicated to the global adoption of decentralized clinical trials and research within life sciences and healthcare, today announced several key initiative updates that will continue to progress throughout 2023. Specialized DTRA teams presented these initiatives during its 2nd Annual Meeting in Boston, MA, from November 6-9, 2022. The meeting was attended by select professionals from its global membership of leaders in decentralized clinical trials (DCTs) including regulators, pharmaceutical and biotechnology sponsors, contract research organizations (CROs) and other service providers, technology companies, research sites, and advocacy leaders.

Key Points: 
  • SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA), a non-profit organization dedicated to the global adoption of decentralized clinical trials and research within life sciences and healthcare, today announced several key initiative updates that will continue to progress throughout 2023.
  • Specialized DTRA teams presented these initiatives during its 2nd Annual Meeting in Boston, MA, from November 6-9, 2022.
  • The Decentralized Trials & Research Alliance ( DTRA ), a non-profit organization, was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research.
  • It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods.

Resorcix, Gat Foods Launch Natural Solution for Preventing TAB Spoilage

Retrieved on: 
Tuesday, July 19, 2022
Research, Pasteurization, CEO, Hebrew University of Jerusalem, Haze, CPG, Method, Solution, Food industry, Bacteria, Spore, Harvard Institute for International Development, Tea, CSO, Water, TAB, Microbiology, Central, JETRO, CTO, Dairy, GMP, Environmental Health (journal), Ministry, EFSA, Ministry of Health (Israel), Eleazar Sukenik, Risk, Wine, Fungus, International, Quality control, Beer, Doctor of Philosophy, FDA, Cannabinoid, Drink, RTD, Food preservation, Bottled water, Alicyclobacillus, Agriculture

GIVA'AT HAIM, Israel, July 19, 2022 /PRNewswire/ -- Gat Foods, part of International Beer Breweries, Ltd. (IBBL), and Israeli startup Resorcix, Ltd., introduce FLAVORWATCHTM, a breakthrough natural, botanical ingredient with inherent ability to prevent Thermophillic Acidophilic Bacteria (TAB) spoilage in clear, fruit-based beverages.

Key Points: 
  • Gat Foods, a leading provider of fruit-based beverage solutions, partnered with Resorcix, to develop FLAVORWATCH,patent-pending,nature-derived solution to the problem of TAB spoilage.
  • The existence of TAB was first documented in 1982 in Germany after a spoilage outbreak in a commercial pasteurized apple juice brand prompted a major recall.
  • Indications of TAB spoilage in beverages include a hazy appearance and, upon opening the bottle, discharge of a smoky, clove-like smell.
  • After several years of extensive R&D, Resorcix partnered with GAT Foods in 2020 to scale up this advanced solution to TAB spoilage.